Literature DB >> 33224790

Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?

Pankaj G Roy1, Didier Verhoeven2.   

Abstract

Entities:  

Year:  2020        PMID： 33224790      PMCID： PMC7667054          DOI： 10.21037/gs.2020.03.12

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  13 in total

1.  Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Virginia F Borges; Cristiano Ferrario; Nathalie Aucoin; Carla Falkson; Qamar Khan; Ian Krop; Stephen Welch; Alison Conlin; Jorge Chaves; Philippe L Bedard; Marc Chamberlain; Todd Gray; Alex Vo; Erika Hamilton
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.

Authors:  Tatiana M Prowell; Julia A Beaver; Richard Pazdur
Journal:  N Engl J Med       Date:  2019-02-14       Impact factor: 91.245

3.  Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

Authors:  Zhimin Shao; Da Pang; Hongjian Yang; Wei Li; Shusen Wang; Shude Cui; Ning Liao; Yongsheng Wang; Chuan Wang; Yuan-Ching Chang; Hweichung Wang; Seok Yun Kang; Jae Hong Seo; Kunwei Shen; Suphawat Laohawiriyakamol; Zefei Jiang; Junjie Li; Julian Zhou; Betsy Althaus; Yixiang Mao; Jennifer Eng-Wong
Journal:  JAMA Oncol       Date:  2020-03-12       Impact factor: 31.777

4.  Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

Authors:  Andreas Schneeweiss; Stephen Chia; Tamas Hickish; Vernon Harvey; Alexandru Eniu; Maeve Waldron-Lynch; Jennifer Eng-Wong; Sarah Kirk; Javier Cortés
Journal:  Eur J Cancer       Date:  2017-12-08       Impact factor: 9.162

5.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

Authors:  Kenji Tamura; Junji Tsurutani; Shunji Takahashi; Hiroji Iwata; Ian E Krop; Charles Redfern; Yasuaki Sagara; Toshihiko Doi; Haeseong Park; Rashmi K Murthy; Rebecca A Redman; Takahiro Jikoh; Caleb Lee; Masahiro Sugihara; Javad Shahidi; Antoine Yver; Shanu Modi
Journal:  Lancet Oncol       Date:  2019-04-29       Impact factor: 41.316

6.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

7.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

8.  Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Authors:  S M Swain; M S Ewer; G Viale; S Delaloge; J-M Ferrero; M Verrill; R Colomer; C Vieira; T L Werner; H Douthwaite; D Bradley; M Waldron-Lynch; A Kiermaier; J Eng-Wong; C Dang
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

9.  Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study.

Authors:  Junjie Li; Zhimin Shao; Binghe Xu; Zefei Jiang; Shude Cui; Jin Zhang; Ning Liao; Jun Jiang; Yongsheng Wang; Quchang Ouyang; Ziwei Ying
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

Review 10.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Authors: 
Journal:  Lancet Oncol       Date:  2017-12-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.